Fighting Overweigth and Obesity
Fighting Overweigth and Obesity
Empros Pharma develops pharmaceutical treatment against overweight and obesity. The EMP16 product is now moving into late stage clinical trials. The early phase trials are finalized, demonstrating a best-in-class safety profile and improved blood glucose control.
A global challenge
Overweight and obesity is a growing global problem affecting an estimated 1.5 billion overweight and 500 million obese individuals (defined as a body mass index, BMI, of 30 or greater). In USA and across Europe between 30-70% of the population are overweight (BMI of 25-29.9) and overweight and obesity has become the fifth leading risk for death globally. Among the most troubling obesity-related trends is an almost 50% increase of overweight children and adolescents during the last decades.
Despite the clearly identified health issues, physicians lack a sufficient tool-box of treatments to be able to halt and reverse the trend. The treatment alternatives are far from adequate when taking effect as well as safety into consideration:
– Life style changes have low compliance and consequently poor long-term effects.
– Available oral medications have a limited efficacy (5-10% weight loss) and often associated with troublesome side-effects.
– Bariatric surgery, is effective but irreversible, and may result in multiple severe adverse effects.
Body mass index (BMI) is defined as the body weight (in kg) in divided by the square of body height (in meter); kg/m2.
Overweight is defined as BMI of 25-29.9 kg/m2.
Obesity is defined as BMI above 30 kg/m2.
EMP16 – a new approach to fighting obesity
Empros Pharma has developed a revolutionary oral drug – EMP16. The main mechanism of action for EMP16 is to delay normal food digestion and absorption processes towards the end of the small intestine. EMP16 thereby support and increase the natural satiety response present in the gastrointestinal system to regulate food intake. An important distinction to other, often hormone based satiety regulating pharmaceuticals (that will act on one or a few of the hormone signalling pathways) is that EMP16 enhances the entire endogenous hormone response in a physiological way. Empros Pharma expects EMP16 to be a safer and more potent method to address the medical need of obese patients.
Features of EMP16 (patent protected):
Advanced modified release formulation with immediate release fractions, gastroresistant frations as well as delayed release fractions.
A multiple unit formulation for improved tolerability, controlled gastric emptying and targeted drug release.
A fixed combination of orlistat and acarbose, two locally active, well established and safe drugs.
Due to its excellent safety profile, overweight subjects with or without decreased glucose tolerance, i.e. 'pre-diabetic' and/or 'pre-obese', could be especially interesting as a treatment group as there are currently no relevant (and safe) alternative products available
The Empros team consists of senior researchers and entrepreneurs with a combined professional experience of well over 100 years. The academic background covers pharmacuticals, nutrition, metabolism, obesity and chemistry as well as clinical trials, pharmaceutical development and pharmaceutical technology. We have a solid background and base with Uppsala University in Sweden.
In addition to the academic background the team has extensive experience of start-ups and life science invention, several of the team members have dozens of medical and/or pharmaceutical ventures on their CV:s as well as senior project management.
Arvid Söderhäll, PhD
Prof. Hans Lennernäs
Chief Scientific Officer
Dr. Ulf Holmbäck
Head of Clinical Program
Head of CMC and QA
Assoc. Prof. Anders Forslund, MD
Chief Medical Officer
Prof. Göran Alderborn
Years of combined professional experience
Weight loss in Target Product Profile
Publications from the Empros Team
Empros Pharma AB was founded late in 2013. The founders, experienced from several previous start-up ventures decided to keep it simple; to establish semi-virtual organisation minimizing the overhead. This has paid off in terms of both burn-rate and agility; we are very proud to have closed a successful phase 2a clinical trial only two-and-a-half years after filing the patent.
The Empros Team is the heart of the organisation, localised in Stockholm and Uppsala.
Our important partners are Recipharm (Stockholm and Bordeaux), Chas. Hude (Copenhagen), Clinical Trial Consultants (Uppsala) and The National Veterinary Institute in Sweden (Uppsala) to mention a few.
Empros Pharma AB is a privately owned Swedish limited liability company. The majority owners are unchanged since the foundation.